Home > Formulary : Adult > Recent Decisions > 2015 >
Decisions 20th January 2015
At the meeting on the 20th January 2015 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Umeclidinium (Incruse Ellipta®) (TLS Blue)
- Approved for COPD maintenance.
Olodaterol (Striverdi Respimat®) (TLS Blue)
- Approved for COPD maintenance.
Beclometasone and formoterol (Fostair® pMDI) (TLS Green)
- Approved for COPD maintenance. Licence extension for use in COPD.
Tiotropium (Respimat®) (TLS Amber specialist recommendation, no SCP)
- Approved for use in asthma for those severe patients not controlled at step 4.
Progesterone (Cyclogest®) pessaries (TLS Red)
- Approved for use in IVF patients and threatened pre-term labour.
More information required
Progesterone (Cyclogest®) pessaries
- Not approved for use in recurrent miscarriage - await imminent results of the PROMISE trial.
Not approved
Tacrolimus mouthwash
- Not approved for inclusion onto the formulary due to a lack of evidence in this cohort.
Shared Care Protocols/TLS Change in Status
Eplerenone
- Agreed to change to amber (specialist recommendation, no SCP) to enable primary care prescribers to initiate if a specialist has recommended treatment.
Ivabradine
- To remain as amber 3 months as the NICE TA267 states that ‘Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.’
Lisdexamfetamine (adults)
- Agreed to change to amber 3 months once a SCP has been developed and approved.
Other decisions:
Indacaterol and glycopyrronium (Ultibro Breezhaler®)
- Now available therefore can be added to the formulary for COPD as per December 2013 decision.